Bachem Holding AG Class B · SIX:BANB

Bachem Holding AG Class B — FY2022 Earnings Presentation

32 slides from Bachem Holding AG Class B's earnings presentation, Mar 7, 2023

  1. Slide 1: Full Year Results 2022

    Slide 1: Full Year Results 2022

    Date | March 7, 2023 Location | Zurich/Zoom Call Name | Thomas Meier, Alain Schaffter

  2. Slide 2: Q&A instructions for the call

    Slide 2: Q&A instructions for the call

    Write to us in the Q&A section anytime and / or use the “Raise Hand” function. At the end of the presentation we will have time for questions. This call will be recorded and playback will be available on bachem.com. 2 Bachem FY Results 2022

  3. Slide 3: Presenters: Thomas Meier, Alain Schaffter, Daniel Grotzky

    Slide 3: Presenters: Thomas Meier, Alain Schaffter, Daniel Grotzky

    Thomas Meier Alain Schaffter Daniel Grotzky (Moderator) CEO CFO Head Group Communication 3 Bachem FY Results 2022

  4. Slide 4: Agenda

    Slide 4: Agenda

    1. Full Year Results 2022 Thomas Meier 2. Financial Review 2022 Alain Schaffter 3. Outlook 2023 Thomas Meier 4. Q&A All 4 Bachem FY Results 2022

  5. Slide 5: Thomas Meier

    Slide 5: Thomas Meier

    Thomas Meier 5 Bachem FY Results 2022

  6. Slide 6: Full Year 2022 highlights: sales, profitability, capacity, portfolio

    Slide 6: Full Year 2022 highlights: sales, profitability, capacity, portfolio

    Sales Profitability • Sales of CHF 531.7m (+5.7%*). • EBITDA CHF 160.5m / margin 30.2%, • Return to growth from H1/22 with strong 2nd half in line with mid-term target of ahead of 30%. with CHF 296.9m (+12.4% against H2/21). • Proposal to increase dividend to CHF 0.75 per • All product categories co

  7. Slide 7: Sales by product category

    Slide 7: Sales by product category

    Change in in CHF million 2022 Change in CHF Sales share local currency Research & Specialties 47.1 + 5.2% + 3.9% 8.9% CMC Development 185.8 + 7.4% + 6.4% 34.9% Commercial API 298.8 + 4.7% + 3.1% 56.2% Total sales 531.7 + 5.7% + 4.3% 100.0% 7 Bachem FY Results 2022

  8. Slide 8: Sales by region

    Slide 8: Sales by region

    Change in in CHF million 2022 Change in CHF Sales share local currency Europe/Asia 316.4 + 17.0% + 17.8% 59.5% North America 215.3 – 7.5% – 11.3% 40.5% Total sales 531.7 + 5.7% + 4.3% 100.0% 8 Bachem FY Results 2022

  9. Slide 9: H1/H2 sales 2016-2022

    Slide 9: H1/H2 sales 2016-2022

    H1/H2 sales in CHF million 350 300 250 200 150 100 50 0 2016 2017 2018 2019 2020 2021 2022 H1 H2 9 Bachem FY Results 2022

  10. Slide 10: Peptides and oligonucleotides market developments

    Slide 10: Peptides and oligonucleotides market developments

    Peptides • Typ 2 Diabetes/obesity drugs put spotlight back on large-volume commercial peptide potential in 2022, industry investments in large scale capacity. • Large-scale multi-year commercial manufacturing agreements. • Ongoing peptide therapeutics approvals by FDA, e.g. pegcetacoplan in Geograph

  11. Slide 11: TIDES Industry Pipeline: Products by Phase

    Slide 11: TIDES Industry Pipeline: Products by Phase

    900 804 TIDES Industry Pipeline 759 800 Products by Phase 700 600 500 400 300 178 200 Peptides 151 88 101 82 50 100 Oligonucleotides 25 15 0 IND/CTA & PC Ph 1 Ph 2 Ph 3 & Pre-Reg Approved Source: Bachem Market Intelligence; IND=investigational new drug, CTA=clinical trial application, PC=pre-clinica

  12. Slide 12: Sales distribution by customer tiers

    Slide 12: Sales distribution by customer tiers

    Sales distribution by customer tiers in % of sales 100 90 80 70 60 50 40 30 20 10 0 2019 2020 2021 2022 Top 5 Top 6-10 Top 11-20 Other 12 Bachem FY Results 2022

  13. Slide 13: NCE pipeline with 175 projects

    Slide 13: NCE pipeline with 175 projects

    • Healthy NCE pipeline with 175 projects Phase No. of projects No. of projects End 2022 end 2021 (all originator, not generics). Preclinical 80 73 • Strong share of industry-wide Ph1-3 Phase 1 39 43 peptide projects. Phase 2 44 43 • Promising Phase III includes likely 2023 submissions. Phase 3 12 11

  14. Slide 14: Oligonucleotides: footprint, Lilly collaboration, tailwinds and headwinds

    Slide 14: Oligonucleotides: footprint, Lilly collaboration, tailwinds and headwinds

    • Bachem footprint across technologies: siRNA, ASOs incl. PMOs; commercial and development presence. • Complete pilot unit (50-200 mmol) for large scale production (1-2 mol). • Long-term collaboration with Lilly (announced April 26, 2022). Long-term Tailwinds • Manufacturing Technology, QC, Engineer

  15. Slide 15: Sustainability progress

    Slide 15: Sustainability progress

    • Increases sustainability score to join the top 2% of all companies rated by EcoVadis and the top 1% among industry peers. • First publication of greenhouse gas emissions via the Carbon Disclosure Project (CDP) with a “B” ranking. • Joined the United Nations Global Compact. • Increased supply chain

  16. Slide 16: Strategic collaboration and large-volume peptide orders

    Slide 16: Strategic collaboration and large-volume peptide orders

    Strategic Collaboration with Large-volume Peptide order Large-volume Peptide order Lilly in Oligonucleotides Customer A Customer B (Apr 2022) (Sep/Dec 2022) (Mar 2023) • Annual order volume with potential c. CHF • Three contracts signed with total • Total committed order volume of more than 100 mill

  17. Slide 17: Contract volumes and capacity expansion

    Slide 17: Contract volumes and capacity expansion

    Contract Volumes «Peptide Order Customer A» CHF 25m CHF150m Total minimum CHF 1bn. «Peptide Order Customer B» Total CHF 500m w. upside potential Oligonucleotide CHF 100m p.a. potential in the next 7 years Collaboration Lilly 2023 2024 2025 2026 2027 2028 2029 2030 2031 Building K Bubendorf ph 1. Bui

  18. Slide 18: Alain Schaffter

    Slide 18: Alain Schaffter

    Alain Schaffter 18 Bachem FY Results 2022

  19. Slide 19: Key financial figures 2022 vs 2021

    Slide 19: Key financial figures 2022 vs 2021

    Change in 2022 2021 Change CHF local currency Sales (in CHF million) 531.7 503.2 + 5.7% + 4.3% EBITDA (in CHF million) 160.5 157.4 + 2.0% + 0.1% in relation to sales 30.2% 31.3% EBIT (in CHF million) 127.2 128.9 – 1.3% – 3.6% in relation to sales 23.9% 25.6% Net income (in CHF million) 100.7 114.7 –

  20. Slide 20: EBITDA margin bridge

    Slide 20: EBITDA margin bridge

    -110bps 31.3 -5.6 6.3 30.2 25.6 -0.9 0.0 -0.6 -0.2 23.9 EBITDA D&A EBIT COGS M&S R&D G&A / EBIT D&A EBITDA margin 2021 margin other margin 2022 margin 2021 2021 income 2022 2022 20 Bachem FY Results 2022

  21. Slide 21: EBITDA margin: 2023 estimates and long-term drivers

    Slide 21: EBITDA margin: 2023 estimates and long-term drivers

    2022 2023 estimates Long-term + Better distribution of + Topline growth ahead + Limited industry Upside COGS across higher of 2022 rates capacity / pricing power sales volumes in H2 + Scale up oligos + Stable cost for M&S in + Project portfolio relation to sales management Downside x Product mix x R

  22. Slide 22: Cash flow development

    Slide 22: Cash flow development

    -67.9 -5.0% 160.6 • Capex cash-out -142.3 97.6 • Acquisition -21.9 92.6 • Sale of securities +101.0 -65.6 92.6 • Dividend -51.6 -35.2 32.9 • Loans -33.5 -63.2 -87.0 -0.2 Operating Cash Operating Cash -57.7 Flow 2021 Flow 2022 Operating Change in Change in Change in Operating Investing Financing Curr

  23. Slide 23: Balance sheet and liquidity

    Slide 23: Balance sheet and liquidity

    699.1 89.2 595.6 31.5 1 298.5 1 383.9 353.2 237.0 177.5 214.2 (14%) (15%) 327.6 277.1 1121.0 1169.7 (86%) (85%) -20.4 -0.3 Liabilities Dec. 31, 2021 Dec. 31, 2022 Dec. 31, 2021 Equity Dec. 31, 2022 Cash and cash equivalents Securities Current financial liabilities Net working capital 23 Bachem FY Re

  24. Slide 24: CAPEX and depreciation

    Slide 24: CAPEX and depreciation

    142.6 130.7 76.4 38.6 33.3 32.7 28.4 23.1 25.9 24.9 26.0 26.8 19.0 13.7 10.4 2018 2019 2020 2021 2022 CAPEX in CHF million Depreciation in CHF million CAPEX in % of sales 24 Bachem FY Results 2022

  25. Slide 25: Long-term industry demand and financing principles

    Slide 25: Long-term industry demand and financing principles

    Long-term industry demand Project Amount Time frame • Peptides: Shift from «100s of kgs to tons». • Oligonucleotides: Shift from «grams to tens of kgs». Bubendorf incl. Building K, c. CHF • Preference for CDMO vs. In-house manufacturing. Until 2026 modernization & office 550m • Need for highly speci

  26. Slide 26: Thomas Meier

    Slide 26: Thomas Meier

    Thomas Meier 26 Bachem FY Results 2022

  27. Slide 27: Customer landscape shifting and TIDES expansion

    Slide 27: Customer landscape shifting and TIDES expansion

    Customer landscape shifting from TIDES expansion into recombinant to chemical synthesis new therapeutic indications New generation of Synthetic manufacturing Peptides Oligonucleotides metabolic disease of peptide generics medicines (diabetes, obesity) 15-20 peptide-based e.g. peptidic complement bey

  28. Slide 28: 2023 outlook: tailwinds and headwinds

    Slide 28: 2023 outlook: tailwinds and headwinds

    • Favorable order situation: mid/large scale equipment very well booked in 2023, confirmed bookings also for 2024/25. • Maturing CMC project portfolio: several late-stage projects with anticipated high material demands upon commercialization. • Shifting product mix: portfolio of commercialized produ

  29. Slide 29: Outlook 2023: sales and profitability

    Slide 29: Outlook 2023: sales and profitability

    Sales Expect to be significantly higher than in the previous year. Profitability Stable EBITDA margin at around 30% anticipated. 29 Bachem FY Results 2022

  30. Slide 30: Q&A

    Slide 30: Q&A

    BACHEM 30 Bachem FY Results 2022

  31. Slide 31: Questions? Send an e-mail

    Slide 31: Questions? Send an e-mail

    Question? Send an e-mail to… ir@bachem.com media@bachem.com 31 Bachem FY Results 2022

  32. Slide 32: Forward-looking statements

    Slide 32: Forward-looking statements

    This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str

Source: Internet Archive copy of bachem.com

More decks from Bachem Holding AG Class B

All 14 Bachem Holding AG Class B decks